Suppr超能文献

共价泛磷脂酰肌醇5-磷酸4-激酶抑制剂的构效关系研究

Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.

作者信息

Manz Theresa D, Sivakumaren Sindhu C, Yasgar Adam, Hall Matthew D, Davis Mindy I, Seo Hyuk-Soo, Card Joseph D, Ficarro Scott B, Shim Hyeseok, Marto Jarrod A, Dhe-Paganon Sirano, Sasaki Atsuo T, Boxer Matthew B, Simeonov Anton, Cantley Lewis C, Shen Min, Zhang Tinghu, Ferguson Fleur M, Gray Nathanael S

机构信息

Department of Cancer Biology, Dana-Farber Cancer Institute, 360 Longwood Avenue, Boston, Massachusetts 02215, United States.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.

出版信息

ACS Med Chem Lett. 2019 Nov 3;11(3):346-352. doi: 10.1021/acsmedchemlett.9b00402. eCollection 2020 Mar 12.

Abstract

Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are important molecular players in a variety of diseases, such as cancer. Currently available PI5P4K inhibitors are reversible small molecules, which may lack selectivity and sufficient cellular on-target activity. In this study, we present a new class of covalent pan-PI5P4K inhibitors with potent biochemical and cellular activity. Our designs are based on THZ-P1-2, a covalent PI5P4K inhibitor previously developed in our lab. Here, we report further structure-guided optimization and structure-activity relationship (SAR) study of this scaffold, resulting in compound , which retained biochemical and cellular potency, while demonstrating a significantly improved selectivity profile. Furthermore, we confirm that the inhibitors show efficient binding affinity in the context of HEK 293T cells using isothermal CETSA methods. Taken together, compound represents a highly selective pan-PI5P4K covalent lead molecule.

摘要

磷脂酰肌醇5-磷酸4-激酶(PI5P4K)是多种疾病(如癌症)中的重要分子参与者。目前可用的PI5P4K抑制剂是可逆的小分子,可能缺乏选择性和足够的细胞靶向活性。在本研究中,我们提出了一类具有强大生化和细胞活性的新型共价泛PI5P4K抑制剂。我们的设计基于THZ-P1-2,这是我们实验室之前开发的一种共价PI5P4K抑制剂。在此,我们报告了对该支架的进一步结构导向优化和构效关系(SAR)研究,得到了化合物 ,其保留了生化和细胞活性,同时显示出显著改善的选择性。此外,我们使用等温CETSA方法证实了这些抑制剂在HEK 293T细胞环境中显示出有效的结合亲和力。综上所述,化合物 代表了一种高度选择性的泛PI5P4K共价先导分子。

相似文献

1
Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.
ACS Med Chem Lett. 2019 Nov 3;11(3):346-352. doi: 10.1021/acsmedchemlett.9b00402. eCollection 2020 Mar 12.
2
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Cell Chem Biol. 2020 May 21;27(5):525-537.e6. doi: 10.1016/j.chembiol.2020.02.003. Epub 2020 Mar 3.
5
Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.
RSC Med Chem. 2023 Apr 17;14(5):934-946. doi: 10.1039/d3md00039g. eCollection 2023 May 25.
6
A targeted library screen reveals a new inhibitor scaffold for protein kinase D.
PLoS One. 2012;7(9):e44653. doi: 10.1371/journal.pone.0044653. Epub 2012 Sep 18.
7
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Biomed Pharmacother. 2020 Aug;128:110249. doi: 10.1016/j.biopha.2020.110249. Epub 2020 May 26.
8
Structure and Characterization of a Covalent Inhibitor of Src Kinase.
Front Mol Biosci. 2020 May 19;7:81. doi: 10.3389/fmolb.2020.00081. eCollection 2020.
9
Phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ), a lipid signalling enigma.
Adv Biol Regul. 2016 May;61:47-50. doi: 10.1016/j.jbior.2015.11.007. Epub 2015 Dec 2.

引用本文的文献

1
PI5P4K inhibitors: promising opportunities and challenges.
FEBS J. 2025 Jan 19. doi: 10.1111/febs.17393.
3
Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.
RSC Med Chem. 2023 Apr 17;14(5):934-946. doi: 10.1039/d3md00039g. eCollection 2023 May 25.
4
Development of potent and selective degraders of PI5P4Kγ.
Eur J Med Chem. 2023 Feb 5;247:115027. doi: 10.1016/j.ejmech.2022.115027. Epub 2022 Dec 24.
5
PIP kinases: A versatile family that demands further therapeutic attention.
Adv Biol Regul. 2023 Jan;87:100939. doi: 10.1016/j.jbior.2022.100939. Epub 2022 Dec 5.
6
Beyond PI3Ks: targeting phosphoinositide kinases in disease.
Nat Rev Drug Discov. 2023 May;22(5):357-386. doi: 10.1038/s41573-022-00582-5. Epub 2022 Nov 14.
7
When PIP Meets p53: Nuclear Phosphoinositide Signaling in the DNA Damage Response.
Front Cell Dev Biol. 2022 May 13;10:903994. doi: 10.3389/fcell.2022.903994. eCollection 2022.
8
Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.
J Med Chem. 2022 Feb 24;65(4):3359-3370. doi: 10.1021/acs.jmedchem.1c01819. Epub 2022 Feb 11.
9
Crucial Players for Inter-Organelle Communication: PI5P4Ks and Their Lipid Product PI-4,5-P Come to the Surface.
Front Cell Dev Biol. 2022 Jan 7;9:791758. doi: 10.3389/fcell.2021.791758. eCollection 2021.
10
Mechanistic roles of mutant p53 governing lipid metabolism.
Adv Biol Regul. 2022 Jan;83:100839. doi: 10.1016/j.jbior.2021.100839. Epub 2021 Nov 23.

本文引用的文献

1
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Cell Chem Biol. 2020 May 21;27(5):525-537.e6. doi: 10.1016/j.chembiol.2020.02.003. Epub 2020 Mar 3.
2
Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.
Mol Cell. 2018 May 3;70(3):531-544.e9. doi: 10.1016/j.molcel.2018.03.037.
3
PIP4K2A regulates intracellular cholesterol transport through modulating PI(4,5)P homeostasis.
J Lipid Res. 2018 Mar;59(3):507-514. doi: 10.1194/jlr.M082149. Epub 2018 Jan 20.
4
Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality.
Nat Commun. 2017 Dec 19;8(1):2200. doi: 10.1038/s41467-017-02287-5.
6
In B cells, phosphatidylinositol 5-phosphate 4-kinase-α synthesizes PI(4,5)P2 to impact mTORC2 and Akt signaling.
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10571-6. doi: 10.1073/pnas.1522478113. Epub 2016 Sep 6.
7
Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system.
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7596-601. doi: 10.1073/pnas.1600934113. Epub 2016 Jun 16.
9
Discovery and pharmacological characterization of a novel small molecule inhibitor of phosphatidylinositol-5-phosphate 4-kinase, type II, beta.
Biochem Biophys Res Commun. 2014 Jul 4;449(3):327-31. doi: 10.1016/j.bbrc.2014.05.024. Epub 2014 May 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验